SC 13G/A | 2017-10-05 | JPMORGAN CHASE & CO | Kite Pharma, Inc. | 1,215,790 | 2.1% | EDGAR |
SC 13G/A | 2017-09-08 | Capital Research Global Investors | Kite Pharma, Inc. | 2,213,371 | 3.8% | EDGAR |
SC 13G/A | 2017-02-15 | Belldegrun Arie | Kite Pharma, Inc. | 3,305,597 | 6.6% | EDGAR |
SC 13G/A | 2017-02-14 | FMR LLC | Kite Pharma, Inc. | 903,573 | 1.8% | EDGAR |
SC 13G/A | 2017-02-14 | VIKING GLOBAL INVESTORS LP | Kite Pharma, Inc. | 0 | 0.0% | EDGAR |
SC 13G/A | 2017-02-13 | Capital Research Global Investors | Kite Pharma, Inc. | 6,109,771 | 12.2% | EDGAR |
SC 13G/A | 2017-02-10 | VANGUARD GROUP INC | Kite Pharma, Inc. | 3,154,258 | 6.3% | EDGAR |
SC 13G | 2017-01-30 | BlackRock Inc. | Kite Pharma, Inc. | 3,369,685 | 6.8% | EDGAR |
SC 13G | 2017-01-26 | JPMORGAN CHASE & CO | Kite Pharma, Inc. | - | - | EDGAR |
SC 13G | 2016-02-29 | VIKING GLOBAL INVESTORS LP | Kite Pharma, Inc. | 2,441,232 | 5.0% | EDGAR |
SC 13G/A | 2016-02-16 | VIKING GLOBAL INVESTORS LP | Kite Pharma, Inc. | 2,207,203 | 4.6% | EDGAR |
SC 13G/A | 2016-02-16 | Capital Research Global Investors | Kite Pharma, Inc. | 5,939,553 | 12.2% | EDGAR |
SC 13G/A | 2016-02-12 | Belldegrun Arie | Kite Pharma, Inc. | 3,303,869 | 6.6% | EDGAR |
SC 13G/A | 2016-02-12 | Alta Partners VIII, L.P. | Kite Pharma, Inc. | 1,761,957 | 3.7% | EDGAR |
SC 13G | 2016-02-12 | FMR LLC | Kite Pharma, Inc. | 3,544,879 | 7.3% | EDGAR |
SC 13G | 2016-02-10 | VANGUARD GROUP INC | Kite Pharma, Inc. | 2,629,342 | 5.4% | EDGAR |
SC 13G | 2015-10-05 | VIKING GLOBAL INVESTORS LP | Kite Pharma, Inc. | 2,688,738 | 6.1% | EDGAR |
SC 13G | 2015-02-12 | Nussbaum Ran | Kite Pharma, Inc. | 2,251,936 | 5.1% | EDGAR |
SC 13G | 2015-02-12 | BONDERMAN DAVID | Kite Pharma, Inc. | 2,408,084 | 5.5% | EDGAR |
SC 13G | 2015-02-12 | Alta Partners VIII, L.P. | Kite Pharma, Inc. | 2,926,059 | 7.0% | EDGAR |